ENTPD3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Suramin (SCHEMBL3161)	1.00	1/20
SCHEMBL12732611	1.00	1/20
SCHEMBL13096782	1.00	1/20
SCHEMBL13105971	1.00	1/20
SCHEMBL21122194	1.00	1/20
SCHEMBL21686991	0.95	1/20
SCHEMBL20370854	0.90	1/20
SCHEMBL16404704	0.86	1/20
SCHEMBL3358966	0.85	1/20
SCHEMBL22767896	0.84	1/20
SCHEMBL16255254	0.84	1/20
SCHEMBL16450974	0.84	1/20
SCHEMBL11510571	0.83	1/20
SCHEMBL11411400	0.82	1/20
SCHEMBL20370856	0.82	1/20
SCHEMBL11582827	0.82	1/20
SCHEMBL11682618	0.82	1/20
SCHEMBL375471	0.80	1/20
SCHEMBL11414391	0.80	1/20
SCHEMBL11426198	0.80	1/20

Clinical trials — most relevant to ENTPD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2	PHASE2	NOT_YET_RECRUITING
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	WITHDRAWN
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients	EARLY_PHASE1	RECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Genetics of Middle Ear Disease	nan	COMPLETED
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study	nan	RECRUITING
PCD New Gene Discovery	nan	COMPLETED
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Human Epididymis Protein 4 in Endometrial Carcinoma	nan	COMPLETED
Genetics of Primary Ciliary Dyskinesia	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Genetic Feature of Congenital Hearing Loss in Chinese Population	nan	NOT_YET_RECRUITING
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients	nan	COMPLETED
Identification of an Asthma Susceptibility Gene on 3P	nan	COMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer	nan	COMPLETED
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)	nan	RECRUITING
miRNAs Profiling in Parkinson's Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ENTPD3 binder may also engage these)

Protein	Name	Similarity
P79784	—	0.995	P79784 →
Q8BFW6	—	0.994	Q8BFW6 →
P97687	—	0.990	P97687 →
Q9MYU4	—	0.989	Q9MYU4 →
O18956	—	0.983	O18956 →
P55772	—	0.979	P55772 →
E1BPW0	—	0.978	E1BPW0 →
ENTPD5	Nucleoside diphosphate phosphatase ENTPD5	0.973	landscape →
O93295	—	0.972	O93295 →
D2GZV9	—	0.972	D2GZV9 →
Q8K0L2	—	0.971	Q8K0L2 →
Q617Y0	—	0.971	Q617Y0 →
Q28CF8	—	0.971	Q28CF8 →
Q21815	—	0.970	Q21815 →
Q2M3T9	—	0.970	Q2M3T9 →
Q6AYF4	—	0.969	Q6AYF4 →
P97278	—	0.969	P97278 →
Q9QYC8	—	0.969	Q9QYC8 →
Q6DYE8	—	0.969	Q6DYE8 →
Q05A56	—	0.969	Q05A56 →
A2A863	—	0.968	A2A863 →
Q1RPR6	—	0.968	Q1RPR6 →
Q6T3U3	—	0.968	Q6T3U3 →
Q641Z7	—	0.968	Q641Z7 →
Q5R748	—	0.968	Q5R748 →
Q5DRK1	—	0.968	Q5DRK1 →
Q29052	—	0.968	Q29052 →
Q9UHG3	—	0.968	Q9UHG3 →
O95498	—	0.967	O95498 →
P43406	—	0.967	P43406 →